Halozyme Shares Decline After German Court Overturns Injunction Against Merck
Halozyme (HALO) shares experienced a decline following a ruling by a Munich court that overturned a preliminary injunction previously issued against Merck & Co. (MRK). The legal dispute centers on patent rights related to the subcutaneous delivery technology used in Merck's blockbuster cancer drug, Keytruda. The decision removes a significant legal hurdle for Merck regarding its injectable formulation of Keytruda. This development is viewed as a setback for Halozyme, which had sought to protect its intellectual property through the injunction, potentially impacting future licensing dynamics or market exclusivity related to the technology.
